Cerenome 과거 순이익 실적
과거 기준 점검 0/6
Cerenome 의 수입은 연평균 -7%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 33.4%의 비율로 증가했습니다. 매출은 연평균 44.8%의 비율로 증가해 왔습니다.
핵심 정보
-7.02%
순이익 성장률
57.40%
주당순이익(EPS) 성장률
| Biotechs 산업 성장률 | 17.04% |
| 매출 성장률 | 44.82% |
| 자기자본이익률 | -477.54% |
| 순이익률 | -620.70% |
| 최근 순이익 업데이트 | 30 Jun 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • Sep 11
CNSY: CNS Delivery Platform And CSF Assay Expansion Will Drive Future Upside
Analysts have reset their price target for Cerenome from $38.00 to $32.50, reflecting updated assumptions on higher projected revenue growth, wider profit margins, a slightly higher discount rate, and a lower future P/E multiple. What’s in the News for Cerenome Cerenome plans a private placement of senior secured convertible notes with 3i, LP with an aggregate original principal amount of US$21,276,596 at a 6% original issue discount, for expected proceeds of about US$20,000,000.24.
내러티브 업데이트 • Jul 06
PSTV: CNSide Coverage And Rebranding Will Reprice Future CNS Oncology Shares
Analysts have trimmed their 12 month price target on Plus Therapeutics to $57 from $65, citing updated fair value assumptions, a modestly higher discount rate, and revised estimates for future revenue growth, profit margins, and P/E multiples. What’s in the News for Plus Therapeutics Plus Therapeutics announced a corporate rebranding to Cerenome, with its Nasdaq ticker expected to change from PSTV to CNSY effective August 3, 2026, according to its mid year business update.
내러티브 업데이트 • Jun 22
PSTV: CNS Oncology Pipeline And New CPT Code Will Drive Upside
Analysts have adjusted their fair value estimate for Plus Therapeutics stock from $1 to $12, citing updated assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple as key drivers of the new price target framework. Analyst Commentary Recent Street research on Plus Therapeutics signals a more cautious tone, with bearish analysts revisiting their assumptions around valuation, execution risk and the pace at which the company may be able to translate its pipeline into financial results.내러티브 업데이트 • Jun 08
PSTV: Future CNS Oncology CPT Codes Will Reprice Shares Despite Downgrades
Analysts have reduced their price target on Plus Therapeutics by $25.50, reflecting updated views on the company’s growth prospects and risk profile following recent research revisions from the Street. Analyst Commentary Recent Street research on Plus Therapeutics highlights a mix of caution and potential upside, with price targets and ratings being recalibrated to reflect updated views on execution risk and commercialization timelines.내러티브 업데이트 • May 24
PSTV: Future Brain Cancer CPT Codes Could Reprice Shares Despite Recent Downgrades
Analysts have cut their price target on Plus Therapeutics by $25.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples following recent downgrades and target revisions. Analyst Commentary Recent research notes highlight a shift in how analysts frame the risk and reward around Plus Therapeutics.내러티브 업데이트 • May 02
PSTV: CNS Delivery And New CPT Codes Will Drive Future Upside
Analysts have adjusted their view on Plus Therapeutics, cutting the average price target by $25.50 while updating their models for fair value, discount rate, profit margin and future P/E to reflect a mix of rating changes and new coverage. Analyst Commentary Recent Street research on Plus Therapeutics reflects a mix of optimism about long term potential and caution around execution and valuation, with one firm initiating coverage positively and others resetting expectations through a downgrade and a lower price target.내러티브 업데이트 • Apr 18
PSTV: Future Brain Cancer CPT Codes And Delivery Technique Could Reprice Shares
Narrative Update The updated analyst price target for Plus Therapeutics moves from about $475 to roughly $65, as analysts cite recent target cuts and a downgrade, along with one newer bullish initiation that together lead to a more tempered but still constructive set of assumptions on revenue growth, margins, and future P/E. Analyst Commentary Recent Street research on Plus Therapeutics shows a mix of caution and optimism, with several firms trimming targets and one newer, more constructive initiation helping to reset expectations rather than support extreme outcomes.내러티브 업데이트 • Apr 03
PSTV: Future Brain Cancer CPT Code And FDA Dialogue Could Reprice Shares
The analyst price target for Plus Therapeutics has shifted from $20.50 to $475.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E. This change is informed by recent mixed Street research that includes a downgrade from D.내러티브 업데이트 • Mar 20
PSTV: Upcoming CNS Milestones And New CPT Code Will Shape Upside Potential
Narrative Update on Plus Therapeutics Analysts have trimmed their price targets on Plus Therapeutics by about $1 to $1.50, reflecting revised views on profit margin potential and valuation, while still citing supportive research coverage for the story. Analyst Commentary Recent research updates paint a mixed picture for Plus Therapeutics, with one initiation taking a constructive stance and other reports trimming price targets by $1 to $1.50.내러티브 업데이트 • Mar 06
PSTV: FDA Pivotal Trial Design And Brain Cancer Pipeline Will Drive Upside
Analysts have reduced their blended price target on Plus Therapeutics by about $0.60, reflecting updated views on fair value, revenue growth expectations, profit margins, and future P/E following recent initiations and target changes from several firms. Analyst Commentary Recent Street research on Plus Therapeutics shows a mix of views, with some firms starting coverage positively while others are taking a more conservative stance through reduced price targets.내러티브 업데이트 • Feb 19
PSTV: Upcoming CNS Milestones And Diagnostics Rollout Will Drive Future Upside
Analysts have trimmed their average Plus Therapeutics price target by $2.50, citing updated assumptions around discount rates, profit margins and a higher future P/E multiple, while still maintaining their fair value estimate at $5.50. Analyst Commentary Bullish Takeaways Bullish analysts point to enough upside against the current trading price to justify a fresh positive view, even after trimming inputs such as discount rates and profit margins.내러티브 업데이트 • Feb 05
PSTV: Upcoming CNS Trials And Diagnostics Expansion Will Drive Upside Potential
Analysts have revised their price targets for Plus Therapeutics lower, with the implied fair value estimate moving from about $9.67 to $5.50 as they incorporate updated assumptions for revenue growth, profit margins, discount rates, and a lower future P/E multiple following recent research updates. Analyst Commentary Recent research updates offer a mixed picture of how analysts are thinking about Plus Therapeutics, with some seeing attractive upside potential and others tempering expectations through lower price targets.내러티브 업데이트 • Jan 22
PSTV: FDA Pivotal Trial Progress Will Drive Future Upside Potential
Narrative Update on Plus Therapeutics Analysts have adjusted their price target for Plus Therapeutics to US$1.63. The change is linked to updated assumptions for discount rate, revenue growth, profit margin, and a revised forward P/E of 49.25x, which reflect their refreshed outlook on the company’s risk and earnings potential.내러티브 업데이트 • Jan 06
PSTV: Advancing Central Nervous System Cancer Trials And Grant Funding Will Drive Upside Potential
Analysts have raised their price target on Plus Therapeutics to US$1.63 per share, reflecting updated assumptions that now pair a revenue growth estimate of 96.95% with a slightly higher discount rate of 7.18%, a lower future P/E of 51.69x, and a modestly adjusted profit margin outlook of 16.24%. What's in the News Presented three clinical data updates at the WFNOS/SNO Annual Meeting in Honolulu covering multiple doses of Rhenium (186Re) Obisbemeda (Reyobiq) for leptomeningeal metastases, including rationale, design, and preliminary Cohort 1 data (Key Developments).내러티브 업데이트 • Dec 15
PSTV: Expanded Brain Cancer Pipeline And Funding Will Drive Upside Potential
Narrative Update on Plus Therapeutics Analysts have raised their price target on Plus Therapeutics to approximately 83.96 from about 114.72, citing a modestly higher assumed discount rate, slightly lower long term profit margins, and somewhat stronger revenue growth expectations that together point to a more balanced, though still optimistic, valuation profile. What's in the News Presented three positive clinical data updates at the WFNOS/SNO Annual Meeting, including early ReSPECT-LM multidose trial results showing REYOBIQ was well tolerated at initial dosing levels and supporting continued dose optimization for leptomeningeal metastases patients (company announcement).내러티브 업데이트 • Nov 04
PSTV: 15 Million Financing And Prefunded Warrants Will Drive Clinical Progress
Analysts have raised their fair value estimate for Plus Therapeutics from $7.88 to $9.67, citing updated revenue forecasts and improved capital structure following recent changes in financing. Analyst Commentary Analyst updates on Plus Therapeutics reflect a balanced perspective on the company’s outlook and recent financing changes.내러티브 업데이트 • Sep 04
15 Million Financing And Oncology Trials Will Secure Clinical Progress
Analysts lowered their price target for Plus Therapeutics from $8.83 to $7.88 primarily due to anticipated equity dilution from recent financing, which increased outstanding shares and warrants, though they remain positive on the company’s long-term outlook. Analyst Commentary Price target reductions reflect anticipated equity dilution following recent financing activities.분석 기사 • Aug 15
We Think Plus Therapeutics (NASDAQ:PSTV) Needs To Drive Business Growth Carefully
NasdaqCM:PSTV 1 Year Share Price vs Fair Value Explore Plus Therapeutics's Fair Values from the Community and select...
새로운 내러티브 • Apr 20
15 Million Financing And Oncology Trials Will Secure Clinical Progress
Strengthened financial position and leadership could drive clinical advancements, potentially boosting future revenue and improving earnings growth.매출 및 비용 세부 내역
매출 및 비용 세부 내역
Cerenome가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 30 Jun 26 | 4 | -26 | 18 | 0 |
| 31 Mar 26 | 5 | -12 | 15 | 0 |
| 31 Dec 25 | 5 | -22 | 12 | 0 |
| 30 Sep 25 | 5 | -21 | 11 | 0 |
| 30 Jun 25 | 5 | -19 | 10 | 0 |
| 31 Mar 25 | 5 | -23 | 11 | 0 |
| 31 Dec 24 | 6 | -13 | 10 | 0 |
| 30 Sep 24 | 6 | -13 | 9 | 0 |
| 30 Jun 24 | 6 | -13 | 9 | 0 |
| 31 Mar 24 | 6 | -12 | 9 | 0 |
| 31 Dec 23 | 5 | -13 | 9 | 0 |
| 30 Sep 23 | 4 | -15 | 10 | 0 |
| 30 Jun 23 | 3 | -17 | 10 | 0 |
| 31 Mar 23 | 1 | -21 | 10 | 0 |
| 31 Dec 22 | 0 | -20 | 10 | 0 |
| 30 Sep 22 | 0 | -19 | 9 | 0 |
| 30 Jun 22 | 0 | -17 | 8 | 0 |
| 31 Mar 22 | 0 | -15 | 8 | 0 |
| 31 Dec 21 | 0 | -13 | 7 | 0 |
| 30 Sep 21 | 0 | -13 | 7 | 0 |
| 30 Jun 21 | 0 | -11 | 6 | 0 |
| 31 Mar 21 | 0 | -10 | 6 | 0 |
| 31 Dec 20 | 0 | -8 | 6 | 0 |
| 30 Sep 20 | 1 | -4 | 6 | 0 |
| 30 Jun 20 | 6 | -2 | 6 | 0 |
| 31 Mar 20 | 6 | -2 | 5 | 0 |
| 31 Dec 19 | 7 | -4 | 5 | 0 |
| 30 Sep 19 | 7 | -7 | 5 | 0 |
| 30 Jun 19 | 2 | -11 | 5 | 0 |
| 31 Mar 19 | 2 | -9 | 5 | 0 |
| 31 Dec 18 | 3 | -11 | 6 | 0 |
| 30 Sep 18 | 4 | -18 | 7 | 0 |
| 30 Jun 18 | 5 | -19 | 8 | 0 |
| 31 Mar 18 | 6 | -24 | 10 | 0 |
| 31 Dec 17 | 6 | -27 | 11 | 0 |
| 30 Sep 17 | 8 | -23 | 11 | 0 |
| 30 Jun 17 | 9 | -24 | 12 | 0 |
| 31 Mar 17 | 10 | -24 | 12 | 0 |
| 31 Dec 16 | 11 | -22 | 12 | 0 |
| 30 Sep 16 | 12 | -20 | 12 | 0 |
| 30 Jun 16 | 12 | -13 | 12 | 0 |
| 31 Mar 16 | 12 | -2 | 12 | 0 |
| 31 Dec 15 | 12 | -19 | 12 | 0 |
| 30 Sep 15 | 12 | -24 | 14 | 0 |
양질의 수익: CNSY 은(는) 현재 수익성이 없습니다.
이익 마진 증가: CNSY는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: CNSY은 수익성이 없으며 지난 5년 동안 손실이 연평균 7% 증가했습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 CNSY의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: CNSY은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(64.6%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: CNSY는 현재 수익성이 없으므로 자본 수익률이 음수(-477.54%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/21 04:37 |
| 종가 | 2026/09/21 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Cerenome, Inc.는 11명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Andrew D'Silva | B. Riley Securities, Inc. |
| John Savin | Edison Investment Research |